Retinopathy of Prematurity: Causes and Treatment

Retinopathy of prematurity (ROP) affects an estimated 14,000–16,000 infants born prematurely in the United States each year, and roughly 400–600 of those children become legally blind as a result (National Eye Institute). The condition is one of the leading preventable causes of childhood blindness worldwide — a fact that makes early screening and timely treatment not just medically important, but genuinely urgent.

What Happens in the Premature Eye

In a full-term pregnancy, retinal blood vessels finish growing by about the 40th week of gestation. Babies born before 31 weeks, or weighing less than 1,500 grams (roughly 3.3 pounds), often arrive before those vessels have completed their delicate branching pattern across the retina's surface.

What follows is a disruption in the normal growth signal. Retinal tissue that still lacks adequate blood supply becomes ischemic — starved for oxygen — and begins releasing vascular endothelial growth factor (VEGF) in abnormally high concentrations. VEGF is a perfectly normal molecule involved in blood vessel formation, but too much of it at the wrong time triggers chaotic, disorganized vessel growth. These fragile new vessels can leak, bleed, or form scar tissue that pulls on the retina and, in the worst cases, detaches it entirely.

The result is a disease that ranges from mild (vessels that eventually normalize on their own) to sight-threatening (retinal detachment requiring surgical intervention).

Known Risk Factors

Gestational age and birth weight remain the two strongest predictors. The American Academy of Ophthalmology screening guidelines recommend examination for all infants born at or before 30 weeks gestational age, or with a birth weight of 1,500 grams or less (American Academy of Ophthalmology).

Beyond prematurity itself, oxygen exposure plays a well-documented role. Supplemental oxygen therapy in neonatal intensive care units (NICUs) is lifesaving, but fluctuating or excessively high oxygen levels can accelerate the abnormal vascular cascade. A landmark multicenter trial — the SUPPORT study, published in the New England Journal of Medicine in 2010 — examined the effects of different oxygen saturation targets in premature infants and found that lower targets (85–89%) reduced severe ROP but raised concerns about mortality compared to higher targets (91–95%) (ClinicalTrials.gov, NCT00233324). That tension between protecting eyes and protecting life remains one of neonatology's more difficult balancing acts.

Other contributing factors include sepsis, blood transfusions, intraventricular hemorrhage, and poor postnatal weight gain. Genetic susceptibility also appears to play a role, though specific gene variants are still under active investigation.

Staging and Classification

ROP is classified by stage (1 through 5), zone (I through III, based on how far from the optic nerve the disease is located), and the presence or absence of "plus disease" — a term describing dilated, tortuous retinal vessels that signal more aggressive progression.

• Stage 1–2: Mild abnormal vessel growth; frequently resolves without treatment.
• Stage 3: Extraretinal fibrovascular proliferation — new vessels grow into the vitreous gel, raising the stakes considerably.
• Stage 4: Partial retinal detachment.
• Stage 5: Total retinal detachment, often with very poor visual prognosis.

The International Classification of Retinopathy of Prematurity, originally published in 1984 and revised in 2005, provides the framework used in clinical decision-making worldwide.

Treatment Approaches

Laser Photocoagulation

For decades, laser therapy has been the standard treatment for threshold ROP. The procedure ablates (destroys) avascular peripheral retina — the tissue producing excess VEGF — to halt abnormal vessel proliferation. The Early Treatment for Retinopathy of Prematurity (ETROP) study, coordinated through the National Eye Institute, demonstrated that treating high-risk pre-threshold ROP reduced unfavorable structural outcomes from 15.6% to 9.1% (National Eye Institute).

Laser therapy is effective but permanently sacrifices peripheral retinal tissue, which can limit side vision.

Anti-VEGF Injections

Intravitreal anti-VEGF agents — notably bevacizumab (Avastin) and ranibizumab (Lucentis) — represent a newer approach that targets the molecular driver directly. The BEAT-ROP trial, published in 2011 in the New England Journal of Medicine, showed that intravitreal bevacizumab significantly reduced recurrence of zone I, stage 3+ ROP compared to laser treatment.

Ranibizumab gained FDA approval for ROP treatment in 2022 under the brand name Lucentis, making it the first anti-VEGF therapy specifically approved for this indication in the United States (FDA).

Anti-VEGF therapy preserves more peripheral retina but carries its own considerations: the drug enters systemic circulation, potentially affecting developing organs, and recurrence rates can be higher than with laser, requiring longer follow-up.

Surgical Intervention

For stage 4 and 5 ROP, vitreoretinal surgery — scleral buckling or vitrectomy — becomes necessary to reattach the retina. Outcomes at these advanced stages are less favorable. Visual recovery after stage 5 detachment remains poor in most cases, which underscores the critical importance of screening and early intervention.

The Role of Screening

Timely screening is the fulcrum on which outcomes turn. The American Academy of Pediatrics, the American Academy of Ophthalmology, and the American Association for Pediatric Ophthalmology and Strabismus jointly recommend initial eye examinations based on gestational age, beginning at 31 weeks postmenstrual age for the most premature infants (AAP, Pediatrics, 2018).

Emerging technologies, including artificial intelligence-based retinal image analysis (such as the i-ROP system), are being validated as tools to improve screening efficiency, particularly in settings with limited access to trained ophthalmologists.

Frequently Asked Questions

Can retinopathy of prematurity resolve without treatment?

Approximately 90% of ROP cases fall into stages 1–2 and regress spontaneously without intervention. Close monitoring remains essential, however, because progression can occur rapidly.

Does ROP always cause blindness?

No. With timely screening and treatment, the majority of infants with ROP retain functional vision. Blindness occurs primarily in untreated or late-detected cases that progress to stages 4–5.

Are there long-term visual effects even after successful treatment?

Children treated for ROP have higher rates of myopia (nearsightedness), strabismus (eye misalignment), and amblyopia compared to the general population. Regular ophthalmologic follow-up through childhood is standard practice.

References

• National Eye Institute — Retinopathy of Prematurity
• American Academy of Ophthalmology — ROP Preferred Practice Pattern
• FDA — Approval of First Treatment for ROP (2022)
• AAP Policy Statement — Screening Examination of Premature Infants for ROP (Pediatrics, 2018)
• ClinicalTrials.gov — SUPPORT Study (NCT00233324)
• National Eye Institute — ETROP Clinical Trials

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)